Literature DB >> 18375498

Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy.

Emma J Birks1, Najma Latif, Karine Enesa, Tonje Folkvang, Le Anh Luong, Padmini Sarathchandra, Mak Khan, Huib Ovaa, Cesare M Terracciano, Paul J R Barton, Magdi H Yacoub, Paul C Evans.   

Abstract

AIMS: The molecular mechanisms that regulate cardiomyocyte apoptosis and their role in human heart failure (HF) are uncertain. Expression of the apoptosis regulator p53 is governed by minute double minute 2 (MDM2), an E3 enzyme that targets p53 for ubiquitination and proteasomal processing, and by the deubiquitinating enzyme, herpesvirus-associated ubiquitin-specific protease (HAUSP), which rescues p53 by removing ubiquitin chains from it. Here, we examined whether elevated expression of p53 was associated with dysregulation of ubiquitin-proteasome system (UPS) components and activation of downstream effectors of apoptosis in human dilated cardiomyopathy (DCM). METHODS AND
RESULTS: Left ventricular myocardial samples were obtained from patients with DCM (n = 12) or from non-failing (donor) hearts (n = 17). Western blotting and immunohistochemistry revealed that DCM tissues contained elevated levels of p53 and its regulators MDM2 and HAUSP (all P < 0.01) compared with non-failing hearts. DCM tissues also contained elevated levels of polyubiquitinated proteins and possessed enhanced 20S-proteasome chymotrypsin-like activities (P < 0.04) as measured in vitro using a fluorogenic substrate. DCM tissues contained activated caspases-9 and -3 (P < 0.001) and reduced expression of the caspase substrate PARP-1 (P < 0.05). Western blotting and immunohistochemistry revealed that DCM tissues contained elevated expression levels of caspase-3-activated DNAse (CAD; P < 0.001), which is a key effector of DNA fragmentation in apoptosis and also contained elevated expression of a potent inhibitor of CAD (ICAD-S; P < 0.01).
CONCLUSION: Expression of p53 in human DCM is associated with dysregulation of UPS components, which are known to regulate p53 stability. Elevated p53 expression and caspase activation in DCM was not associated with activation of both CAD and its inhibitor, ICAD-S. Our findings are consistent with the concept that apoptosis may be interrupted and therefore potentially reversible in human HF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18375498     DOI: 10.1093/cvr/cvn083

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  51 in total

1.  Resveratrol protects against doxorubicin-induced cardiotoxicity in aged hearts through the SIRT1-USP7 axis.

Authors:  Thomas K Sin; Bjorn T Tam; Benjamin Y Yung; Shea P Yip; Lawrence W Chan; Cesar S Wong; Michael Ying; John A Rudd; Parco M Siu
Journal:  J Physiol       Date:  2015-02-09       Impact factor: 5.182

2.  Altered ubiquitin-proteasome signaling in right ventricular hypertrophy and failure.

Authors:  Viswanathan Rajagopalan; Mingming Zhao; Sushma Reddy; Giovanni Fajardo; Xuejun Wang; Shannamar Dewey; Aldrin V Gomes; Daniel Bernstein
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-05-31       Impact factor: 4.733

Review 3.  Sirtuin 3, Endothelial Metabolic Reprogramming, and Heart Failure With Preserved Ejection Fraction.

Authors:  Heng Zeng; Jian-Xiong Chen
Journal:  J Cardiovasc Pharmacol       Date:  2019-10       Impact factor: 3.105

Review 4.  The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy.

Authors:  Lucie Carrier; Saskia Schlossarek; Monte S Willis; Thomas Eschenhagen
Journal:  Cardiovasc Res       Date:  2009-07-17       Impact factor: 10.787

5.  DNA Damage Response/TP53 Pathway Is Activated and Contributes to the Pathogenesis of Dilated Cardiomyopathy Associated With LMNA (Lamin A/C) Mutations.

Authors:  Suet Nee Chen; Raffaella Lombardi; Jennifer Karmouch; Ju-Yun Tsai; Grace Czernuszewicz; Matthew R G Taylor; Luisa Mestroni; Cristian Coarfa; Priyatansh Gurha; Ali J Marian
Journal:  Circ Res       Date:  2019-03-15       Impact factor: 17.367

Review 6.  Proteasome dysfunction in cardiomyopathies.

Authors:  Jennifer E Gilda; Aldrin V Gomes
Journal:  J Physiol       Date:  2017-03-16       Impact factor: 5.182

Review 7.  Role of various proteases in cardiac remodeling and progression of heart failure.

Authors:  Alison L Müller; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

8.  Primary proteasome inhibition results in cardiac dysfunction.

Authors:  Joerg Herrmann; Christine Wohlert; Ardan M Saguner; Ana Flores; Lisa L Nesbitt; Alejandro Chade; Lilach O Lerman; Amir Lerman
Journal:  Eur J Heart Fail       Date:  2013-04-24       Impact factor: 15.534

9.  Regulation of posttranscriptional modification as a possible therapeutic approach for retinal neuroprotection.

Authors:  Yoko Ozawa; Toshihide Kurihara; Kazuo Tsubota; Hideyuki Okano
Journal:  J Ophthalmol       Date:  2010-11-07       Impact factor: 1.909

Review 10.  The ubiquitin proteasome system in human cardiomyopathies and heart failure.

Authors:  Sharlene M Day
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-03-11       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.